Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.81
ETRM's Cash to Debt is ranked higher than
56% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ETRM: 4.81 )
Ranked among companies with meaningful Cash to Debt only.
ETRM' s 10-Year Cash to Debt Range
Min: 1.29  Med: 4.27 Max: N/A
Current: 4.81
Equity to Asset 0.18
ETRM's Equity to Asset is ranked lower than
91% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ETRM: 0.18 )
Ranked among companies with meaningful Equity to Asset only.
ETRM' s 10-Year Equity to Asset Range
Min: 0.18  Med: 0.56 Max: 0.62
Current: 0.18
0.18
0.62
F-Score: 4
Z-Score: -55.53
M-Score: 5.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -32893.67
ETRM's Operating margin (%) is ranked lower than
98% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. ETRM: -32893.67 )
Ranked among companies with meaningful Operating margin (%) only.
ETRM' s 10-Year Operating margin (%) Range
Min: -7250.48  Med: -7250.48 Max: -7250.48
Current: -32893.67
Net-margin (%) -33510.13
ETRM's Net-margin (%) is ranked lower than
98% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. ETRM: -33510.13 )
Ranked among companies with meaningful Net-margin (%) only.
ETRM' s 10-Year Net-margin (%) Range
Min: -7543.41  Med: -7543.41 Max: -7543.41
Current: -33510.13
ROE (%) -326.42
ETRM's ROE (%) is ranked lower than
97% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ETRM: -326.42 )
Ranked among companies with meaningful ROE (%) only.
ETRM' s 10-Year ROE (%) Range
Min: -1135.7  Med: -140.32 Max: -77.38
Current: -326.42
-1135.7
-77.38
ROA (%) -165.66
ETRM's ROA (%) is ranked lower than
93% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. ETRM: -165.66 )
Ranked among companies with meaningful ROA (%) only.
ETRM' s 10-Year ROA (%) Range
Min: -962.06  Med: -86.74 Max: -60.09
Current: -165.66
-962.06
-60.09
ROC (Joel Greenblatt) (%) -5652.96
ETRM's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. ETRM: -5652.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ETRM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4834.37  Med: -2401.78 Max: -578.16
Current: -5652.96
-4834.37
-578.16
EBITDA Growth (3Y)(%) -23.60
ETRM's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. ETRM: -23.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ETRM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -59.80 Max: -23.6
Current: -23.6
EPS Growth (3Y)(%) -23.20
ETRM's EPS Growth (3Y)(%) is ranked lower than
75% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ETRM: -23.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ETRM' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.1  Med: -54.90 Max: 41.9
Current: -23.2
-69.1
41.9
» ETRM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ETRM Guru Trades in Q1 2014

Chuck Royce 1,285,000 sh (unchged)
» More
Q2 2014

ETRM Guru Trades in Q2 2014

Chuck Royce 1,060,000 sh (-17.51%)
» More
Q3 2014

ETRM Guru Trades in Q3 2014

Chuck Royce 648,600 sh (-38.81%)
» More
Q4 2014

ETRM Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ETRM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.50
ETRM's P/B is ranked lower than
97% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. ETRM: 13.50 )
Ranked among companies with meaningful P/B only.
ETRM' s 10-Year P/B Range
Min: 2.1  Med: 4.83 Max: 14
Current: 13.5
2.1
14
P/S 243.75
ETRM's P/S is ranked lower than
135% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. ETRM: 243.75 )
Ranked among companies with meaningful P/S only.
ETRM' s 10-Year P/S Range
Min: 0  Med: 135.00 Max: 294
Current: 243.75
0
294
Current Ratio 1.01
ETRM's Current Ratio is ranked lower than
89% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. ETRM: 1.01 )
Ranked among companies with meaningful Current Ratio only.
ETRM' s 10-Year Current Ratio Range
Min: 1.01  Med: 3.34 Max: 9.46
Current: 1.01
1.01
9.46
Quick Ratio 0.81
ETRM's Quick Ratio is ranked lower than
83% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ETRM: 0.81 )
Ranked among companies with meaningful Quick Ratio only.
ETRM' s 10-Year Quick Ratio Range
Min: 0.81  Med: 3.28 Max: 9.46
Current: 0.81
0.81
9.46
Days Inventory 12.00
ETRM's Days Inventory is ranked higher than
97% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. ETRM: 12.00 )
Ranked among companies with meaningful Days Inventory only.
ETRM' s 10-Year Days Inventory Range
Min: 1840.73  Med: 1840.73 Max: 1840.73
Current: 12
Days Sales Outstanding 522.09
ETRM's Days Sales Outstanding is ranked lower than
99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. ETRM: 522.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
ETRM' s 10-Year Days Sales Outstanding Range
Min: 61.03  Med: 61.03 Max: 61.03
Current: 522.09

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.00
ETRM's Price/Tangible Book is ranked lower than
88% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.01 vs. ETRM: 14.00 )
Ranked among companies with meaningful Price/Tangible Book only.
ETRM' s 10-Year Price/Tangible Book Range
Min: 1.88  Med: 4.56 Max: 44.22
Current: 14
1.88
44.22
Earnings Yield (Greenblatt) (%) -104.26
ETRM's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. ETRM: -104.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ETRM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -347.84  Med: 0.00 Max: 0
Current: -104.26
-347.84
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 1 4 14
EPS($) -0.33 -0.22 -0.19
EPS without NRI($) -0.33 -0.22 -0.19

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:BY8N.Germany,
EnteroMedics Inc was incorporated in Minnesota on December 19, 2002 and later reincorporated in Delaware on July 22, 2004. It is a medical device company with approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries that recognize the European CE Mark. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's proprietary neuroblocking technology, VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company's initial product, the Maestro Rechargeable System uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has regulatory approval to sell its product in Australia, the European Economic Area and other countries that recognize the European CE Mark and do not have any other source of revenue. The Company relies on third-party manufacturers and suppliers for the production of its Maestro Rechargeable System. The Company competes in the market for obesity treatment with surgical obesity procedures and various devices used to implement neurostimulation and gastric stimulation systems. The Company also competes against the manufacturers of pharmaceuticals that are directed at treating obesity. The Company's opeartors include: Roche, GlaxoSmithKline, Arena Pharmaceuticals, Inc., VIVUS, Inc. and Orexigen Therapeutics, Inc. The Company also competes with several private early-stage companies developing neurostimulation devices for application to the gastric region and related nerves for the treatment of obesity. The Company has 32 national stage patent applications, including applications in Australia, China, India, Europe and Japan, one granted Chinese application and one granted application in Japan. In addition, the Company is the exclusive licensee to three U.S. patents owned by the Mayo Foundation for Medical Education and Research, which are unrelated to the Company's VBLOC therapy. Maestro Rechargeable System is regulated by the FDA as a medical device under the Federal Food, Drug, and Cosmetic Act (FFDCA) and the regulations promulgated under the FFDCA.
» More Articles for ETRM

Headlines

Articles On GuruFocus.com
Kevin Douglas Bets on EnteroMedics; Popeyes and AMERCO Top Estimates May 28 2015 
Canaccord Genuity Remains Bullish on EnteroMedics Following Q4 Earnings Feb 19 2015 
Analysts Are Bullish On EnteroMedics Following FDA Approval Of Obesity Treatment Jan 16 2015 
EnteroMedics Inc. Reports Operating Results (10-K) Mar 07 2011 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 08 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 06 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) May 07 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 16 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 07 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
ENTEROMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Sep 01 2015
5 Breakout Stocks to Trade for Big Gains Aug 28 2015
ENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... Aug 25 2015
Mark B. Knudson, Ph.D., EnteroMedics Founder, Chairman, President and Chief Executive Officer, to... Aug 25 2015
Mark B. Knudson, Ph.D., EnteroMedics Founder, Chairman, President and Chief Executive Officer, to... Aug 25 2015
Edited Transcript of ETRM earnings conference call or presentation 6-Aug-15 3:00pm GMT Aug 24 2015
ENTEROMEDICS INC Financials Aug 19 2015
ENTEROMEDICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Aug 18 2015
10-Q for EnteroMedics, Inc. Aug 09 2015
ENTEROMEDICS INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
EnteroMedics Inc Earnings Call scheduled for 11:00 am ET today Aug 06 2015
EnteroMedics reports 2Q loss Aug 06 2015
EnteroMedics reports 2Q loss Aug 06 2015
ENTEROMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 06 2015
EnteroMedics Reports Second Quarter 2015 Financial Results Aug 06 2015
Q2 2015 EnteroMedics Inc Earnings Release - Time Not Supplied Aug 06 2015
EnteroMedics Reports Second Quarter 2015 Financial Results Aug 06 2015
EnteroMedics to Present at the Canaccord Genuity 35th Annual Growth Conference Aug 05 2015
EnteroMedics to Present at the Canaccord Genuity 35th Annual Growth Conference Aug 05 2015
ENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Aug 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK